Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
1.56
Dollar change
-0.03
Percentage change
-1.89
%
IndexRUT P/E- EPS (ttm)-0.51 Insider Own64.53% Shs Outstand73.70M Perf Week-17.02%
Market Cap114.97M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float26.14M Perf Month-11.86%
Enterprise Value112.78M PEG- EPS next Q- Inst Own10.23% Short Float2.60% Perf Quarter-43.07%
Income-33.80M P/S24.10 EPS this Y- Inst Trans0.63% Short Ratio0.45 Perf Half Y-
Sales4.77M P/B14.43 EPS next Y- ROA-245.79% Short Interest0.68M Perf YTD-10.86%
Book/sh0.11 P/C40.92 EPS next 5Y- ROE- 52W High13.68 -88.60% Perf Year-
Cash/sh0.04 P/FCF- EPS past 3/5Y-36.87% - ROIC-414.78% 52W Low1.30 20.00% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y3.32% - Gross Margin-10.83% Volatility26.99% 14.31% Perf 5Y-
Dividend TTM- EV/Sales23.64 EPS Y/Y TTM-77.65% Oper. Margin-289.61% ATR (14)0.26 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.94 Sales Y/Y TTM8.97% Profit Margin-707.92% RSI (14)40.12 Recom-
Dividend Gr. 3/5Y- - Current Ratio2.16 EPS Q/Q-101.16% SMA20-12.11% Beta- Target Price-
Payout- Debt/Eq0.08 Sales Q/Q34.73% SMA50-22.24% Rel Volume0.64 Prev Close1.59
Employees75 LT Debt/Eq0.02 Earnings- SMA200-64.45% Avg Volume1.52M Price1.56
IPOAug 29, 2025 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume970,377 Change-1.89%
Today 11:26AM
Feb-12-26 08:30AM
Feb-10-26 04:05PM
Feb-05-26 04:05AM
Jan-29-26 04:05PM
09:00AM Loading…
Jan-13-26 09:00AM
Jan-12-26 08:30AM
Jan-07-26 08:00AM
Jan-06-26 08:00AM
Dec-30-25 08:00AM
Dec-26-25 06:25AM
Dec-24-25 09:36AM
Dec-18-25 08:55AM
08:30AM
Dec-09-25 04:05PM
04:05PM Loading…
Dec-03-25 04:05PM
Nov-26-25 07:00AM
Nov-19-25 04:05PM
Nov-14-25 07:00AM
Nov-12-25 08:00AM
Nov-03-25 08:00AM
Oct-24-25 03:07PM
Oct-08-25 10:51AM
Sep-22-25 08:00AM
Sep-15-25 08:00AM
Sep-10-25 08:00AM
Sep-09-25 04:05PM
Sep-08-25 07:00AM
Sep-02-25 04:05PM
Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.